Our pilot study addresses this topic: first we further investigated the role of BACE1 activity as an early biomarker for AD and estimated the diagnostic accuracy of the assay; then we compared the accuracy of the BACE1 assay with that obtained with serum Aβ forms. Here, BACE1 is linked to Alzheimer disease.